Given that many of the metabolic diseases are major risk factors and contributors to increased morbidity and mortality from cardiovascular disease (CVD) [127,128], further investigation of visfatin with regards to its implication and therapeutic target potentials in cardiovascular–metabolic disorders is warranted. The gene discussed is NAMPT; the disease is metabolic disease.